Chinese firms had enjoyed a privileged position because of the country’s regulatory system. Photo: Alamy

Pharma firms face shake-up with China’s plan to bulk-buy drugs

  • Pilot programme involves major cities clubbing together to purchase certain medicines, driving down prices
  • Chinese companies that have invested heavily in R&D stand best chance of survival
Topic |   Health in China

TOP PICKS

Chinese firms had enjoyed a privileged position because of the country’s regulatory system. Photo: Alamy
READ FULL ARTICLE